Faeth Therapeutics, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-05-31: Study NCT05864144; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Completed.
- 2020-04-01: Study NCT04217720; Company role Lead sponsor; Phase Phase 2; Status Withdrawn.
- 2019-11-11: Study NCT04034225; Company role Lead sponsor; Phase Phase 1, Phase 2; Status Terminated.
- 2016-12: Study NCT03120832; Company role Lead sponsor; Phase Phase 1; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-05-31 | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Lead sponsor | Phase 1, Phase 2 | Completed | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreatic Cancer; Gastric Cancer; Esophageal Cancer; Prostate Cancer; Uterine Cancer; Cervix Cancer; Ovarian Cancer; Kidney Cancer; Bladder Cancer; Thyroid Cancer; Melanoma; Sarcoma; Advanced Cancer; Metastatic Cancer; Refractory Cancer; Non Small Cell Lung Cancer; Merkel Cell Carcinoma | 98 | 2026-06-02 |
| 2020-04-01 | NCT04217720 SNS-301 Monotherapy in High Risk MDS and CMML | Lead sponsor | Phase 2 | Withdrawn | Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia (CMML) | 0 | 2023-01-01 |
| 2019-11-11 | NCT04034225 Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | Lead sponsor | Phase 1, Phase 2 | Terminated Results posted | Squamous Cell Carcinoma of the Head and Neck | 25 | 2021-06-28 |
| 2016-12 | NCT03120832 Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients | Lead sponsor | Phase 1 | Completed Results posted | Prostate Cancer | 12 | 2018-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |